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Abstract: Intervertebral disc degeneration is a major source of back pain. For intervertebral disc
regeneration after herniation a fast closure of anulus fibrosus (AF) defects is crucial. Here, the use
of the C-C motif chemokine ligand 25 (CCL)25 in comparison to differentiation factors such as
transforming growth factor (TGF)β3, bone morphogenetic protein (BMP)2, BMP7, BMP12, and BMP14
(all in concentrations of 10, 50 and 100 ng/mL) was tested in an in vitro micro mass pellet model
with isolated and cultivated human AF-cells (n = 3) to induce and enhance AF-matrix formation.
The pellets were differentiated (serum-free) with supplementation of the factors. After 28 days all
used factors induced proteoglycan production (safranin O staining) and collagen type I production
(immunohistochemical staining) in at least one of the tested concentrations. Histomorphometric
scoring revealed that TGFβ3 delivered the strongest induction of proteoglycan production in all three
concentrations. Furthermore, it was the only factor able to facilitate collagen type II production, even
higher than in native tissue samples. CCL25 was also able to induce proteoglycan and collagen type
I production comparable to several BMPs. CCL25 could additionally induce migration of AF-cells
in a chemotaxis assay and therefore possibly aid in regeneration processes after disc herniation by
recruiting AF-cells.
Keywords: anulus fibrosus; CCL25; TECK; chemotaxis; differentiation; extracellular matrix;
tissue regeneration
1. Introduction
Back pain is one of the main health problems in industrialized countries [1]. In Germany, 60–70%
of the adult population is affected by back pain every year. Thus, back pain is a significant health
problem in Germany, which has considerable economic consequences. The costs of treatment for back
pain in Germany are 48 billion Euros a year, divided in direct treatment costs (46%) and indirect costs
(54%) due to economical production loss [2]. One major source of back pain is intervertebral disc
(IVD) degeneration. The presently preferred method of surgical treatment of patients with herniated
IVDs remedies the symptoms only temporarily. In 15–25% of operated patients, pain occurs after
1–2 years and 6% of patients have to be re-operated [3]. In herniated discs the leaking nucleus pulposus
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is removed but ruptures in the anulus fibrosus (AF) remain. That is a major problem that often
leads to reherniation. To avoid this, solid barriers are implanted for closure of the remaining gap [4].
The disadvantage is that for fixation these barriers have to be integrated in the vertebral bodies and do
not improve regeneration of damaged AF tissue. Also, loosening and dislocation can occur, causing
severe pain [5]. Therefore, first experiments in a sheep model towards the closure of an AF defect with
natural tissue from the submucosal porcine small intestine were performed and showed improved
outcomes compared to untreated defects [6]. Also transplantation of cell-seeded biomaterials for
closure of the defect and regeneration of the AF tissue are in focus of research studies [7]. In a two
step procedure, autologous cells have to be isolated, expanded, and several weeks later combined
with the biomaterial. There are currently no therapies available in clinical routine that support natural
regeneration of the AF in a favourable one step procedure.
Another approach to enhance tissue regeneration and subsequent AF closure is the application
of growth factors. Already in 1991, Thompson et al. reported effects of various growth factors on
cell proliferation and proteoglycan (PG) synthesis in organ cultures of canine IVD cells. Extracellular
matrix (ECM) PGs play an important functional role due to their high water-binding capacity in the
disc [8]. Factors such as BMP2 [9], BMP7 [10], and BMP14 [11] led to increased PG synthesis in various
animal cell cultures in vitro or to an increase in AF tissue thickness in animal models. In a comparative
in vitro study in which various BMPs were adenovirally transduced into bovine AF cells, almost all
BMPs were found to be effective in increasing PG content and collagen type II formation. BMP13
was found to be the most effective BMP [12]. In human cells, an increase in PG content could also be
determined in vitro following addition of BMP7 to AF cells [13].
Another group of interesting factors are chemokines. However, so far, they were not discussed in
context of AF cells or AF closure. As chemotactic cytokines they are able to induce cell migration and
could possibly initiate AF cell recruitment from intact surrounding AF tissue into the defect area of
the herniated discs and lead to an induction of tissue regeneration. Among this group of factors, C-C
motif chemokine ligand (CCL)25 also known as thymus—expressed chemokine (TECK), has shown a
high recruitment potential on mesenchymal stromal cells [14,15], which are often discussed in context
of IVD regeneration [16].
Platelet lysate from platelet-rich plasma (PRP) contains a concentrate of various numbers of
growth factors and cytokines. Among them are different members of the TGFβ superfamily, such as
BMP2, BMP4, BMP7, BMP12, TGFβ2 and TGFβ3, known to have an impact on synthesis of IVD and
cartilage [17] ECM synthesis. Platelet lysate from PRP is also known to induce glycosaminoglycan
production in AF-derived cells [18].
Focussing on our overall aim to establish a regenerative approach for AF closure, based on
implantation of biomaterials supplemented with growth factors and/or cell recruiting factors like
chemokines, the aim of our current study was to compare the effect of BMP2, -7, -12, -14, TGFβ3, which
were found as a component in PRP [17], CCL25 and PRP-derived platelet lysate on the formation of
extracellular AF matrix, in a 3D high-density cell culture assay. Formation of collagens and PGs by
human AF cells will be analyzed by histology and immunohistochemistry. Moreover, for the first time,
using a Boyden-chamber chemotaxis assay, we want to analyse migratory effects of CCL25 on human
AF cells. Besides the migratory effect, the main question of this study is if CCL25 is able to support cell
matrix production of AF in vitro comparable to known factors of the TGFβ-superfamily.
2. Results
2.1. Chemotaxis Assay
To evaluate the potential of CCL25 to induce cell migration of AF-derived cells, concentrations of
500, 750 and 1000 nM CCL25 were applied in the Boyden-chamber chemotaxis assay. Cells derived
from mild (Pfirmann-score II–III) and severe (Pfirrmann-score IV–V) degenerated human AF tissues
of 3 independent donors each were tested in triplicates. All concentrations induced a significant
Int. J. Mol. Sci. 2018, 19, 2207 3 of 13
(p ≤ 0.001) increase of migrated cells compared to cells in unstimulated control groups without CCL25
(Figure 1). In general, absolute cell numbers of migrated cells were slightly higher for cells from
donors with mild degenerated AF. For cells derived from tissues of donors 1 and 2, 750 nM showed
the highest dose-dependent migratory effect. For cells derived from donor 3, 500 nM revealed the
highest effect. Cultures derived from severe degenerated AF tissue of donors 4 and 5 demonstrated
the highest number of migrated cells at 750 nM while cells from donor 6 showed the highest migration
at 1000 nM CCL25.
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Figure 1. Chemotaxis assay. Migration of lumbar AF cells derived from donors with mild disc 
degeneration (donors 1–3) and severe disc degeneration (donors 4–6) (all measured in triplicates; 
error bars: standard deviation). Significant increased migration (* p ≤ 0.001) was found in all CCL25 
concentrations (500, 750, and 1000 nM) compared to unstimulated controls. There were no significant 
differences between concentrations. Also, no significant differences between cells form mild and 
severe degenerated AF for same CCL25 concentrations were detected. 
2.2. Scratch-Wound Assay 
To determine a migratory effect of PRP-derived platelet lysate on AF cells a scratch-wound 
assay was performed with PRP concentrations of 1%, 2.5%, and 5% in standard cultivation medium 
as serum replacement. The assay was performed with the cells from the same donors as the 
chemotaxis assay (mild degenerated AF tissues: donors 1–3; severe degenerated AF tissues: donors 
4–6) and each measured in triplicates. The scratch was applied in a confluent layer of AF cells 
(Figure 2A,B). Closure of the gap by cell growth was documented after 24 h (Figure 2C) and 48 h 
(Figure 2D). Results are exemplarily shown for 2.5% PRP (Figure 2A–D). For comparison, exemplary 
images of the closing gap after 48 h were given for 1% PRP (Figure 2E), for 5% PRP (Figure 2F), 10% 
human serum supplemented medium (Figure 2G), and for serum-free medium (Figure 2H). Mean 
results from TScratch software to determine the percentage of the open area after 48 h compared to 
the scratch at 0 h revealed that 1% (mean of 23.8% open space) and 2.5% of PRP (mean of 22.5% open 
space) showed the most efficient closure of the gap. Medium with 5% PRP (mean of 35.2% open 
space) was slightly less effective than standard medium with 10% human serum (mean of 32.2% 
open space). Serum-free medium left an open space of 62.5% in mean. All PRP concentrations and 
the 10% human serum group were significantly lower than the serum-free group for cells derived 
from mild and severe degenerated tissues (* p < 0.05). There were no significant differences between 
mild and severe groups for the same medium (Figure 2I). 
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2.2. Scratch- ound Assay
To deter ine a migratory effect of PRP-derived platelet lysate on AF cells a scratch-wound assay
was performed with PRP concentrations of 1%, 2.5%, and 5% in standard cultivation medium as
serum replacement. The assay was performed with the cells from the sa e donors as the chemotaxis
assay (mild degenerated AF tissues: donors 1–3; severe degenerated AF tissues: donors 4–6) and each
measured in triplicates. The scratch was applied in a confluent layer of AF cells (Figure 2A,B). Closure
of the gap by cell growth was documented after 24 h (Figure 2C) and 48 h (Figure 2D). Results are
exemplarily shown for 2.5% PRP (Figure 2A–D). For comparison, exemplary images of the closing gap
after 48 h were given for 1% PRP (Figure 2E), for 5% PRP (Figure 2F), 10% human serum supplemented
medium (Figure 2G), and for serum-free medium (Figure 2H). Mean results from TScratch software to
determine the percentage of the open area after 48 h compared to the scratch at 0 h revealed that 1%
(mean of 23.8% open space) and 2.5% of PRP (mean of 22.5% open space) showed the most efficient
closure of the gap. Medium with 5% PRP (mean of 35.2% open space) was slightly less effective
than standard medium with 10% human serum (mean of 32.2% open space). Serum-free medium
left an open space of 62.5% in mean. All PRP concentrations and the 10% human serum group were
significantly lower than the serum-free group for cells derived from mild and severe degenerated
tissues (* p < 0.05). There were no significant differences between mild and severe groups for the same
edium (Figure 2I).
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Figure 3. Pellet formation of AF cells (exemplarily donor 7, 100 ng/mL supplemented factor or 2.5%
PRP or unstimulated) showed an increase of stiffness and a decrease in size, except of TGFβ3 stimulated
pellets. There, also an increase of size was visible (scale: scale line distance = 1 mm; main scale line
distance = 5 mm).
As shown by immunohistochemical staining, 28 days of induction with CCL25 led to a weak
formation of collagen type I (Figure 4A), while TGFβ3 induced samples revealed an intense staining
(Figure 4B) both compared to native tissue (Figure 4C) and non-induced controls (Figure 4D).
Histomorphometric analysis of the immunohistochemical staining revealed that collagen type I was
formed in nearly all TGFβ3 induced pellet cultures, reaching levels similar to native tissue samples
in all supplemented concentrations (Figure 5). Also, the cult res induced with 10 g/mL BMP7 and
100 ng/mL BMP12 demonstrated a similar result. CCL25 (10 ng/mL), BM 14 (100 ng/mL) and BMP2
treatment r sulted in slightly lower histomorphom tric values, while the induction ith platelet lysate
from PRP was even lower but still above non-induced samples. For PRP supplementation of the
medium, 2.5% were used. This value showed the best results in the scratch-wound assays indicating
an appropriate concentration for future cell recruitment-based approaches.
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Figure 4. Histological and immunohistochemical staining. Exemplary visualization of collagen
type I immunohistochemical staining of CCL25 induced (A), TGFβ3 induced (B) AF cells in pellet
cultures; native AF tissue (C), and non-induced (D) AF cells in pellet cultures; collagen type II
immunohistochemical staining of CCL25 indu ed (E), TGFβ3 induced (F) AF cells in pellet cultures;
native AF tissue (G), and non-indu d (H) AF cells in pellet cultures; safranin O staining of CCL25
induced (I), TGFβ3 induced (J) AF cells in pellet cultures; native AF tissue (K), and non-induced (L)
AF cells in pellet cultures.
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Figure 5. Histomorphometric analysis of collagen and proteoglycan formation. Collagen type I (A) and
type II (B) stainings were analyzed histomorphometrically and the red stained areas calculated and
given as a percentage of the sample. Histomorphometric analysis of safranin O staining determined
the red value of the samples (C). Average values of the 3 donors were given as horizontal bars (___).
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Formation of collagen type II rich matrix was not seen in CCL25 induced samples (Figure 4E) and
only measurable amounts were observed in TGFβ3 induced pellets in all concentrations (Figure 4F)
in a comparable level to native tissue (Figure 4G). Non-induced controls showed no collagen type II
production (Figure 4H). Histomorphometric analysis confirmed this data. A further induction was
only seen in 50 and 100 ng/mL BMP2, 50 ng/mL BMP12, and 10 ng/mL BMP14 induced pellets of
cells of donor 7 (Figure 5).
Safranin O staining demonstrated an enhanced PG production in CCL25 induced samples
comparable to native tissue (Figure 4I,K). An even stronger PG production was found in TGFβ3
induced pellets (Figure 4J). The massive production of safranin O by TGFβ3 was confirmed in all
3 concentrations. Non-induced pellets revealed no PG formation by safranin O staining (Figure 4L).
Furthermore, BMP2, BMP12, and BMP14 induced samples showed an increased safranin O staining
of PGs in 100 ng/mL induced samples (Figure 5). Taken together PRP and BMP7, could only induce
collagen type I production, whereas BMP2, BMP12, BMP14, and CCL25 were able to induce collagen
type I and PG synthesis. Only TGFβ3 induced all 3 tested ECM components. However, PG production
was up to 7 times higher compared to native AF tissue.
3. Discussion
In our study, we could demonstrate for the first time, that the chemokine CCL25 is able to induce
migration of human AF-derived cells. Furthermore, CCL25 could stimulate PG and collagen type I
production in our in vitro high-density 3D micromass pellet culture system. Our targets to demonstrate
ECM production in our pellet system were collagen type I and type II since they are the most prominent
in the AF ECM. These two types of collagen fibrils are making up approximately 70% of the dry weight
of the AF with collagen type I more prominent in the outer part of the AF and collagen type II in the
inner part [19,20]. Furthermore, safranin O staining was used to demonstrate PGs, making about 20%
of the wet weight of the AF [20]. In the cell migration assay and the scratch assay AF cells from mild
and severe degenerated tissues were used with only marginal differences in the results. This is in
accordance with other studies where proliferation, migration, and ECM formation of AF cells derived
from mild and severe degenerated AF tissues were analyzed [21]. A different study analyzed the
PG/collagen ratio in AF tissues from different stages of IVD degeneration and donor ages [22]. Here,
was also no correlation of the measured results to degeneration grade of the IVD and donor age.
Considering the PG production, BMP2, BMP12, and BMP14 showed similar results compared to
CCL25 and native AF tissue. Only TGFβ3 enabled up to 7 fold higher PG content in the extracellular
matrix than in native AF tissue. Since in the AF the PG content is only 20% of the wet weight [20],
the 7 fold higher induction seems to outbalance the concentration of collagens and PG in TGFβ3
induced samples. BMP7 and platelet lysate derived from PRP were only able to induce a small amount
of PG production.
In this study, cells were cultivated with 2.5% platelet lysate of PRP. This led to an increased
proliferation and migration of AF cells in the scratch-wound assay, but only to a minimal induction
of PGs in the pellet assay. Other studies with bovine cells used higher amounts of 25–50% platelet
lysate to demonstrate PG induction in AF cell cultures [18]. In alginate 3D cultures with porcine cells,
10% PRP was used to effectively stimulate AF cells for matrix and collagen production [23]. The use
of 2.5% platelet lysate might have been optimal for AF cell proliferation and migration but not for
PG production. Similar results were achieved in a study with 5% PRP in a scaffold-based 3D AF
model. An enhanced proliferation of the cells was induced but no production of PGs and collagens
were detected [21]. For PRP in our study, only a minor collagen type I induction compared to the
other tested factors was detectable in our 3D pellet system, whereas collagen type II was not visible
similar to non-induced cells. The absence of collagen type II secretion was also observed in BMP7 and
CCL25 treated pellets. BMP2 stimulation resulted in an increased collagen type II staining for cells of
one donor treated with 50 and 100 ng/mL. The same cells also responded to 50 ng/mL BMP12 and
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10 ng/mL BMP14 inductions. Only TGFβ3 stimulation revealed a similar stained area compared to
native tissues indicating collagen type II production.
In contrast to the weak collagen type II staining, collagen type I staining demonstrated larger
stained areas. Most effective collagen type I production of BMP2 treated pellets was found in
concentrations of 10 and 50 ng/mL dependent on the donor. BMP7 showed the highest collagen type I
induction using 10 ng/mL. BMP12 and BMP14 presented their largest stained areas of collagen type I
using 100 ng/mL induction, with BMP12 achieving a similar level compared to native tissue samples.
All three concentrations of TGFβ3 resulted in similar efficient collagen type I induction. Besides the
factors that are known for collagen induction [12], also the chemokine CCL25 was able to do so in a
ratio similar to BMP14 when supplemented in a concentration of 10ng/mL.
Since CCL25 was able to induce collagen type I and PG production in AF cells it might be an
interesting candidate for our overall aim to establish a regenerative approach for AF closure, based on
implantation of biomaterials supplemented with growth/differentiation factors and/or cell recruiting
factors. With the capability to recruit AF cells and then after recruitment to induce ECM synthesis in
these cells an additional growth/differentiation factor might not be needed. A corresponding receptor
of CCL25 is CCR9. It was already demonstrated that CCR9 is expressed in AF cells on gene expression
level [24], but CCL25 could not induce a significant migration in that study. In our study, the CCL25
induced migration was detectable in cells derived from severe and mild degenerated AF tissue in
a range of 500–1000 nM. The use of CCL25 to induce migration in other mesenchymal cells (bone
marrow derived mesenchymal stem/stroma cells [15], periosteum derived mesenchymal progenitor
cells [14] or mesenchymal progenitors derived from subchondral cortico-spongious bone [25]) was
already tested in concentrations of 1,10, 50,100, 250, 500, 750, and 1000 nM. There, results showed
that an optimal dose-dependent migration with CCL25 was always induced in concentration between
500–1000 nM (mesenchymal stem/stromal cells: 1000 nM, periosteum derived progenitor cells:
500 nM, progenitors from cortico-spongious bone: 1000nM). Lower concentrations led to migration
but were barely statistical significant compared to unstimulated cells. Therefore, we focused our
experiments on the target concentrations 500, 750, and 1000 nM. For the other factors used in our
pellet differentiation assay an inducing migratory effect on AF-derived cells is not described in the
literature. A recent test demonstrated that TGFβ3 was not able to induce the migration of these cells
in vitro [21]. The chemotactic effects of different BMPs like the used BMP2, BMP7, and also TGFβ on
articular chondrocytes were already evaluated. No significant increase of migration was found using
the three mentioned growth factors [26].
Nevertheless, besides the impact on PG and collagen production members of the TGFβ-
superfamily are in discussion. Besides their ability to induce collagen and PG production in AF
cells [9–13] they may also have an impact on AF ossification. It was reported that in concentrations of
1 µg/mL BMP2 and TGFβ3 induce ossification in the AF in an intervertebral disc rabbit explant model.
Therefore, these factors were also suggested to be used in similar concentrations to induce osseous
fusion of intervertebral discs [27]. When transferring the results of our study for AF regeneration,
a supplementation of these two factors, especially as seen for TGFβ3 may lead to an ossification of
newly formed tissue or the surrounding AF. In human clinical applications, BMP2 is used for spinal
fusion [28]. Nevertheless, the use of BMP2 for this application is also discussed due to occurring
side effects. Depending on the spinal area, the use of BMP2 may lead to ectopic bone formation
or inflammation causing severe dysphagia and airway compromise [29]. BMP7 combined with an
autograft was tested in clinical trial studies but could not demonstrate a significant increase of spinal
fusion compared to an autograft alone without BMP7 [30,31]. Also, BMP14 is considered for spinal
fusion. In a rabbit model BMP14 in combination with a Healos carrier (cross-linked type I collagen with
hydroxyapatite coating) showed a significantly higher spinal fusion rate than only an autograft control
group [32]. Two clinical trials considering the safety, tolerability and the preliminary effectiveness of
rhBMP14 are ongoing [33]. Therefore for an application in a regenerative approach for the closure
of AF defects these mentioned factors might not be the best choice. The impact of CCL25 on AF
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ossification is unknown so far. Also the application of PRP might be of interest. Despite showing only
a weak induction of collagen type I PRP can be prepared from the patient’s own blood enabling an
autologous application.
Taken together, here we demonstrate for the first time that the chemokine CCL25 is able to
stimulate the migration of AF cells and, surprisingly, to induce PG and collagen type I production in a
3D micromass pellet culture system of human AF derived cells on a similar level compared to several
BMPs. Considering the overall aim of regenerating AF defects based on implantation of biomaterials
supplemented with growth/differentiation factors and/or cell recruiting factors, CCL25 provides
in vitro all recommended abilities. With the capability to recruit AF cells (migration assay) and after
recruitment to induce ECM synthesis (3D pellet model) in these cells an additional supplementation or
a combination of growth/differentiation factors might not be needed.
Therefore, CCL25 represents an interesting candidate for factor induced AF regeneration and
closure of AF defects in vivo. Further studies for CCL25 in in vivo approaches should be performed
to prove the capability of CCL25 to recruit cells from healthy AF tissue to damaged tissue areas and
further to induce these cells to matrix formation after recruitment. In that case, a factor release system
might be of interest to provide a proper CCL25 distribution with a high released concentration in the
cell recruitment phase and a constant lower release during the collagen and PG synthesis phase.
4. Materials and Methods
4.1. Preparation of Human Serum and PRP
Human serum was prepared from full coagulated blood bags of healthy donors (German Red
Cross, Berlin, Germany). Serum was centrifuged at 3500× g for 10 min without a brake. Supernatant
was inactivated for 30 min at 56 ◦C. The serum was stored at −20 ◦C until used.
PRP (German Red Cross) (n = 5) of normal, healthy donors was pooled and frozen at −20 ◦C.
For preparing the platelet lysate an aliquot of pooled PRP was thawed at 4 ◦C and centrifuged at
1600× g at 4 ◦C for 10 min. Supernatant was frozen again at −20 ◦C. After an additional thawing and
centrifugation, the freezing of the supernatant and the thawing procedure was repeated for a third
time. The final supernatant containing the platelet lysate was used in experiments.
4.2. Isolation and Cultivation of Anulus Fibrosus Cells
Cells were isolated from native human lumbar AF tissue samples of different degeneration
grades provided by volunteering donors undergoing spinal surgery. All donors gave their informed
consent for inclusion before they participated in the study. The study was conducted in accordance
with the Declaration of Helsinki. The study was approved by the ethics committee of the
Charité-Universitätsmedizin Berlin (project identification code EA2/102/15 approved 06/08/2015).
Scoring of degeneration grades was performed according to MRI images using Pfirrmann score [34].
Tissue samples were rinsed and a small fragment of 0.3 cm × 0.3 cm was separated, embedded
in a cryomold containing TissueTek (Sakura Finetek, Staufen, Germany), and frozen in liquid
nitrogen. The frozen tissue was stored at −80 ◦C for histological and immunohistochemicalstainings.
The remaining tissue was minced in 1 mm2 sized fragments and placed in a spinner flask containing
30 mL isolation medium (Dulbeccos modified Eagle Medium (1 g/L glucose) (Biochrom, Berlin,
Germany), 10% human allogenic serum, 1% penicillin/streptomycin (Biochrom), 10,000 U collagenase
CLS II (Biochrom), 30 U collagenase P (Roche, Mannheim, Germany), and 1000 U hyaluronidase
(Sigma-Aldrich, Munich, Germany)). After digestion over night cells were rinsed and the remaining
fragments were removed. Cells were seeded in cell culture flasks with a density of 10,000 cells/cm2
and cultivated with growth medium (Dulbeccos modified Eagle Medium (1 g/L glucose), 10% human
allogenic serum, 1% penicillin/streptomycin, 2 ng/mL human fibroblast growth factor 2 (Peprotech,
Hamburg, Germany)). At 80–90% of confluence cells were harvested with trypsin/EDTA and seeded
with a density of 5000 cells/cm2. Cultivation was performed up to passage 4.
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4.3. Chemotaxis Assay
Chemotaxis assays to analyse the recruiting potential of the chemokine CCL25 (Peprotech) on
AF cells were performed using 96-multiwell ChemoTx plates with 8 µm pore size (Neuroprobe,
Gaithersburg, MD, USA). Cells of donors with mild (Pfirmann-score II–III) and severe (Pfirmann-score
IV–V) disc degeneration grades (n = 3 each) were used for chemotaxis analysis. The chemokine CCL25
(Peprotech) was diluted in serum-free medium (Dulbeccos modified Eagle Medium (1 g/L glucose)
(Biochrom), 1% penicillin/streptomycin (Biochrom), 0.5% bovine serum albumin (Sigma-Aldrich)) in
concentrations of 500, 750, and 1000 nM and 37.5 µL were filled in triplicates in the lower chamber.
The membrane was placed on top and 30,000 cells in a volume of 40 µL serum-free medium were
placed on the upper side of the membrane. After 20 h of incubation non-migrated cells on the upper
side of the membrane were removed and migrated cells on the lower side were stained using the
Hemacolorstaining Kit (Merck, Darmstadt, Germany). Stained cells were counted in two microscopic
images (40× magnification) and extrapolated to the whole well. Statistical significances of migration
for stimulated cells with 500, 750, and 100 nM compared to unstimulated cells, between concentration
and between cells from mild and severe degenerated tissue were calculated. Normal distribution
was determined using the D’Agostino and Pearson omnibus normality test. Statistical significance
was analyzed using t-test of GraphPad Prism v5 software (GraphPad Software, La Jolla, CA, USA).
Differences were considered significant at p ≤ 0.001.
4.4. Scratch-Wound Assay
The scratch-wound assay was used to evaluate an appropriate PRP concentration for cell
migration. AF cells of donors with mild and severe disc degeneration grades (n=3 each) were used.
Cells at passage 4were seeded in triplicates in 24-well plates with a density of 15,000 cells/well in a
volume of 500 µL and cultivated until confluence. With the tip of a pipette a scratch was made in the
confluent layer cutting cell layers in halves. Growth medium containing 10% human serum, serum-free
medium with ITS+ supplement (Sigma-Aldrich) and medium with either 1%, 2.5% or 5% of activated
PRP were used to replace the standard growth medium. Every medium was also supplemented with
the anti-coagulant acid citrate dextrose (ACD) (Sigma-Aldrich) in a ratio of 1:1 to avoid coagulation of
PRP. Cells were allowed to grow to replace the empty space left by the scratch for 48 h. Photographs
were taken directly after applying the scratch, 24 and 48 h later. The ratio between the residual open
area after 48 h and the initial prepared scratch area was calculated and given as percentage of the
open area after the initial scratch [35]. Normal distribution was determined using the D’Agostino and
Pearson omnibus normality test. Statistical significances of migrated cells compared to serum-free
controls and between cells from mild and severe degenerated tissue were calculated using t-test of
GraphPad Prism v5 software. Differences were considered significant at p ≤ 0.001.
4.5. Factor Screening Assay
A micromass pellet system was used to determine a factor enhancing AF matrix formation. After
the third passage, AF cells of three individual donors were washed twice with serum-free differentiation
medium (Dulbeccos modified Eagle Medium (4.5 g/L glucose) (Biochrom), 2% HEPES (Biochrom),
1% penicillin/streptomycin (Biochrom), 1% ITS+ supplement (Sigma-Aldrich), 0.1 µM dexamethasone
(Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 0.17 mM ascorbic acid (Sigma-Aldrich),
0.35 mM proline (Sigma-Aldrich)) and 250,000 cells were transferred to 15 mL tubes. To the serum-free
medium BMP2, BMP7, BMP12 (growth differentiation factor 7 (GDF7)), BMP14 (GDF5), TGFβ3 or
CCL25 (all Peprotech) were added in concentrations of 10, 50 or 100 ng/mL. Additionally, samples
with 2.5% PRP and non-stimulated controls without any other factor were prepared. Six samples of
each factor and each concentration were prepared. Over all, 120 pellet cultures in 20 different media
were prepared for cells of each donor. The pellets were cultivated for 28 days with a medium change
three times a week. Samples were taken at day 2, day 14, and day 28. Each pellet was placed in a
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cryomold and embedded in TissueTek (Sakura Finetek). After freezing in liquid nitrogen the pellets
were stored at −80 ◦C until used for histological and immunohistochemical analysis.
4.6. Histological and Immunohistochemical Analysis of Anulus Fibrosus Matrix Production
To demonstrate collagen production immunohistochemical staining were carried out. To show
extracellular matrix production safranin O staining was performed to determine PG formation. In brief,
frozen samples in TissueTek were sectioned with a thickness of 6 µm and transferred to a glass
slide. For the verification of collagen type I and type II production, immunohistochemical detection
was performed using primary monoclonal mouse anti-human antibodies against collagen type I
(BioRad, Puchheim, Germany) and collagen type II (Merck). For visualisation the DAKO EnVision
Kit (DAKO, Hamburg, Germany) was used according to the manufacturer’s protocol. In brief,
the cryosections were incubated with primary antibodies for 40 min. The secondary horseradish
peroxidase labeled goat anti-mouse antibody solution was also applied for 40 min. Last, the samples
were incubated with the substrate AEC for 10 min and counterstained for 10 min with hematoxylin
(DAKO). For safranin O staining of sulphated PGs the samples on the glass slides were stained with
0.7% safranin O (Sigma-Aldrich) in 66% ethanol for 30 min. For counterstaining, cell nuclei were
stained with 0.2% Fast Green FCF (Sigma-Aldrich) solved in 75% acetic acid for 1 min. Photographs of
the staining were taken and analyzed histomorphometrically. For the determination of red values for
safranin O staining and the red stained areas of immunohistochemical collagen types I and II staining
a histomorphometric analysis was performed as described before [36].
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